Pomerantz LLP is investigating potential securities fraud claims against Boston Scientific Corporation (BSX) following a significant drop in its stock price. This investigation stems from the company’s release of fourth-quarter 2025 financial results, which showed lower-than-expected sales in its electrophysiology division. On February 4, 2026, Boston Scientific’s stock fell by $16.12 per share, or 17.6%, closing at $75.50.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
Pomerantz LLP is investigating potential securities fraud claims against Boston Scientific Corporation (BSX) following a significant drop in its stock price. This investigation stems from the company’s release of fourth-quarter 2025 financial results, which showed lower-than-expected sales in its electrophysiology division. On February 4, 2026, Boston Scientific’s stock fell by $16.12 per share, or 17.6%, closing at $75.50.